MX2008002057A - Complejo de inclusion del inhibidor del factor xa con ciclodextrina. - Google Patents
Complejo de inclusion del inhibidor del factor xa con ciclodextrina.Info
- Publication number
- MX2008002057A MX2008002057A MX2008002057A MX2008002057A MX2008002057A MX 2008002057 A MX2008002057 A MX 2008002057A MX 2008002057 A MX2008002057 A MX 2008002057A MX 2008002057 A MX2008002057 A MX 2008002057A MX 2008002057 A MX2008002057 A MX 2008002057A
- Authority
- MX
- Mexico
- Prior art keywords
- cyclodextrin
- factor
- inhibitor
- inclusion complex
- venous thrombosis
- Prior art date
Links
- 229920000858 Cyclodextrin Polymers 0.000 title abstract 4
- 229940123583 Factor Xa inhibitor Drugs 0.000 title abstract 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title 1
- 206010047249 Venous thrombosis Diseases 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- OFJRNBWSFXEHSA-UHFFFAOYSA-N 2-(3-amino-1,2-benzoxazol-5-yl)-n-[4-[2-[(dimethylamino)methyl]imidazol-1-yl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide Chemical compound CN(C)CC1=NC=CN1C(C=C1F)=CC=C1NC(=O)C1=CC(C(F)(F)F)=NN1C1=CC=C(ON=C2N)C2=C1 OFJRNBWSFXEHSA-UHFFFAOYSA-N 0.000 abstract 1
- NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 abstract 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 abstract 1
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 abstract 1
- 206010051055 Deep vein thrombosis Diseases 0.000 abstract 1
- 229960003886 apixaban Drugs 0.000 abstract 1
- -1 hydroxypropyl- Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229950010535 razaxaban Drugs 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70907705P | 2005-08-17 | 2005-08-17 | |
| US11/464,519 US20070191306A1 (en) | 2005-08-17 | 2006-08-15 | FACTOR Xa INHIBITOR FORMULATION AND METHOD |
| PCT/US2006/031801 WO2007022165A2 (en) | 2005-08-17 | 2006-08-16 | Factor xa inhibitor inclusion complex with cyclodextrin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2008002057A true MX2008002057A (es) | 2008-04-16 |
Family
ID=37654897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2008002057A MX2008002057A (es) | 2005-08-17 | 2006-08-16 | Complejo de inclusion del inhibidor del factor xa con ciclodextrina. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20070191306A1 (https=) |
| EP (1) | EP1924291A2 (https=) |
| JP (1) | JP2009504746A (https=) |
| AR (1) | AR055377A1 (https=) |
| BR (1) | BRPI0614827A2 (https=) |
| CA (1) | CA2619214A1 (https=) |
| MX (1) | MX2008002057A (https=) |
| PE (1) | PE20070378A1 (https=) |
| TW (1) | TW200800270A (https=) |
| WO (1) | WO2007022165A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR074052A1 (es) | 2008-10-22 | 2010-12-22 | Array Biopharma Inc | Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa |
| SMT202000093T1 (it) * | 2009-06-16 | 2020-03-13 | Pfizer | Forme di dosaggio di apixaban |
| IN2012DN06587A (https=) * | 2010-02-25 | 2015-10-23 | Bristol Myers Squibb Co | |
| AR091567A1 (es) * | 2012-06-27 | 2015-02-11 | Takeda Pharmaceutical | Preparacion liquida, metodo, kit de inyeccion |
| MY179191A (en) * | 2012-09-26 | 2020-10-30 | Pfizer | Apixaban liquid formulations |
| CN104650072B (zh) * | 2013-11-18 | 2016-03-16 | 成都苑东生物制药股份有限公司 | 一种吡啶类衍生物 |
| ES2987474T3 (es) | 2016-04-04 | 2024-11-15 | Loxo Oncology Inc | Formulaciones líquidas de (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-IL)-pirazolo[1,5-A]pirimidin-3-IL)-3-hidroxipirrolidina-1-carboxamida |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| ES2836222T3 (es) | 2016-05-18 | 2021-06-24 | Loxo Oncology Inc | Preparación de (S)-N-(5-((R)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida |
| CN115715770B (zh) * | 2021-08-24 | 2024-01-26 | 新领医药技术(深圳)有限公司 | 阿哌沙班透皮贴剂及其制备方法 |
| NL2029536B1 (en) | 2021-10-27 | 2023-05-26 | Pharma Data S A | Apixaban suspension and preparation method |
| US12214075B2 (en) | 2021-10-27 | 2025-02-04 | Pharma-Data Research And Development Single Member S.A. | Apixaban suspension and preparation method |
| WO2026003874A1 (en) * | 2024-06-28 | 2026-01-02 | Cipla Limited | Injectable compositions of apixaban |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6407079B1 (en) * | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
| US4745105A (en) * | 1986-08-20 | 1988-05-17 | Griffin Charles C | Low molecular weight heparin derivatives with improved permeability |
| US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) * | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| UA57734C2 (uk) * | 1996-05-07 | 2003-07-15 | Пфайзер Інк. | Комплекси включення арилгетероциклічних солей |
| JPH10194996A (ja) * | 1996-12-25 | 1998-07-28 | Janssen Pharmaceut Nv | アシル化シクロデキストリン含有製薬組成物 |
| US6339099B1 (en) * | 1997-06-20 | 2002-01-15 | Dupont Pharmaceuticals Company | Guanidine mimics as factor Xa inhibitors |
| FR2773801B1 (fr) * | 1998-01-19 | 2000-05-12 | Sanofi Sa | Nouveaux pentasaccharides, procedes pour leurs preparations et compositions pharmaceutiques les contenant |
| DE60006407T2 (de) * | 1999-09-13 | 2004-09-09 | 3-Dimensional Pharmaceuticals, Inc. | Azazykloalkanone serin-protease-hemmer |
| TWI331526B (en) * | 2001-09-21 | 2010-10-11 | Bristol Myers Squibb Pharma Co | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
| CA2461202C (en) * | 2001-09-21 | 2011-07-12 | Donald Pinto | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
-
2006
- 2006-08-15 US US11/464,519 patent/US20070191306A1/en not_active Abandoned
- 2006-08-16 JP JP2008527053A patent/JP2009504746A/ja not_active Withdrawn
- 2006-08-16 AR ARP060103576A patent/AR055377A1/es not_active Application Discontinuation
- 2006-08-16 TW TW095130020A patent/TW200800270A/zh unknown
- 2006-08-16 MX MX2008002057A patent/MX2008002057A/es not_active Application Discontinuation
- 2006-08-16 CA CA002619214A patent/CA2619214A1/en not_active Abandoned
- 2006-08-16 WO PCT/US2006/031801 patent/WO2007022165A2/en not_active Ceased
- 2006-08-16 EP EP06789766A patent/EP1924291A2/en not_active Withdrawn
- 2006-08-16 BR BRPI0614827-1A patent/BRPI0614827A2/pt not_active IP Right Cessation
- 2006-08-17 PE PE2006000998A patent/PE20070378A1/es not_active Application Discontinuation
-
2009
- 2009-08-04 US US12/535,016 patent/US20090291913A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20090291913A1 (en) | 2009-11-26 |
| TW200800270A (en) | 2008-01-01 |
| JP2009504746A (ja) | 2009-02-05 |
| BRPI0614827A2 (pt) | 2011-04-19 |
| WO2007022165B1 (en) | 2007-10-18 |
| PE20070378A1 (es) | 2007-05-04 |
| CA2619214A1 (en) | 2007-02-22 |
| AR055377A1 (es) | 2007-08-22 |
| EP1924291A2 (en) | 2008-05-28 |
| WO2007022165A2 (en) | 2007-02-22 |
| US20070191306A1 (en) | 2007-08-16 |
| WO2007022165A3 (en) | 2007-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2008002057A (es) | Complejo de inclusion del inhibidor del factor xa con ciclodextrina. | |
| SV2009003227A (es) | Composiciones de inhibidores de chk 1 ref. x-17672 | |
| DE602007010152D1 (de) | Mehrstufige schicht | |
| CO2019009449A2 (es) | Combinaciones fungicidas | |
| NO20083143L (no) | Fremgangsmate og arrangement for innmating av kjemikalier i en prosesstrom | |
| AR037755A1 (es) | Composiciones acuosas con contenido de metronidazol | |
| FR2884818A1 (fr) | Procede de preparation d'acide acrylique a partir de glycerol | |
| NO20072839L (no) | 4-hydroksybenzomorfaner | |
| CY1115299T1 (el) | Αναστολεις mtor στη θεραπεια των ενδοκρινικων ογκων | |
| ECSP077247A (es) | Trans - clomifeno para el tratamiento de la hipertrofia prostatica benigna, cancer prostatico, hipogonodismo, trigliceridos elevados y alto colesterol | |
| ATE510553T1 (de) | Beta-2-glycoprotein 1 als angiogenesehemmer | |
| DE60314115D1 (de) | Syntaktisches polyolefin enthaltende zusammensetzung zum beschichten von rohren | |
| DE502007001593D1 (de) | Regal-fachboden | |
| TW200619847A (en) | Photosensitive composition, compound for use in the photosensitive composition, and pattern-forming method using the photosensitive composition | |
| DE502006000627D1 (de) | Flüssigwaschmittel mit Bleichmittelzusatz | |
| DE602004001445D1 (de) | Zusammensetzungen mit fluorierten kohlenwasserstoffen und oxygenierten lösungsmitteln | |
| NO20075140L (no) | Fremgangsmater og preparater for modulering av vaskulaer integritet | |
| AR054243A1 (es) | Metodos y composiciones para retardar la liberacion de quimicos de tratamiento | |
| NO20084468L (no) | Fremgangsmate ved bruk av klebriggjorende silikonmatriks i underjordiske formasjoner | |
| CY1110202T1 (el) | Νεοι συνδυασμοι ενος αντι εμετικου παραγοντα και ενος αναστολεα της εγκεφαλινασης | |
| ATE454112T1 (de) | Brustprothese | |
| DE602007008588D1 (de) | Verfahren zur herstellung von alkylencarbonat | |
| ES2233695T3 (es) | Composicion que retarda el enrejillado. | |
| NO20082852L (no) | Faramsoytisk blanding samt bruk av alfa-hydroksy karbonylforbindelser som reduksjonsmidler | |
| ATE392269T1 (de) | Verfahren zum anbringen eines faserigen isoliermittels aus zellulose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |